Literature DB >> 481968

Pulmonary vasodilator action of tolazoline.

B W Goetzman, J M Milstein.   

Abstract

The pulmonary vasodilator action of tolazoline in newborn lambs was shown to be mediated via histamine receptors. Maximal changes in pulmonary vascular resistance, deltaPVR, were calculated as percents of the base line value, %deltaPVR. The mean %deltaPVR after tolazoline, 1 mg/kg, was -25 +/- 4% for eight lambs. Four lambs then received the histamine H1 receptor antagonist, diphenhydramine, and the mean %deltaPVR due to tolazoline was -12 +/- 4%. Four lambs received the H2 receptor antagonist, metiamide, and the mean %delta PVR due to tolazoline was -18 +/- 5%. After both H1 and H2 antagonists, the mean %deltaPVR due to tolazoline was +6 +/- 8%. Therefore, both histamine H1 and H2 receptors were involved in the vasodilator response to tolazoline.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 481968     DOI: 10.1203/00006450-197908000-00014

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  4 in total

1.  Duodenal perforation associated with tolazoline.

Authors:  R G Wilson; R J George; W J McCormick; P A Raine
Journal:  Arch Dis Child       Date:  1985-09       Impact factor: 3.791

2.  Treatment of persistent fetal circulation syndrome of the newborn. Comparison of different doses of tolazoline.

Authors:  P Monin; C Dubruc; P Vert; P L Morselli
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

3.  Cardiovascular effects of tolazoline and ranitidine.

Authors:  A Bush; C M Busst; W B Knight; E A Shinebourne
Journal:  Arch Dis Child       Date:  1987-03       Impact factor: 3.791

4.  Clinical and echocardiographic evidence suggesting afterload reduction as a mechanism of action of tolazoline in neonatal hypoxemia.

Authors:  G G Sandor; A J Macnab; F A Akesode; V J Ebelt; M R Pendray; W Y Ling; M W Patterson; M A Tipple
Journal:  Pediatr Cardiol       Date:  1984 Apr-Jun       Impact factor: 1.655

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.